CBSA seizes over 23kg of Khat at Pearson airport
The Canadian Border Services Agency seized approximately 23 kilograms of the banned stimulant khat at Pearson International Airport earlier this month.
The shipment was sent from the U.K. and was intercepted on July 10, the CBSA said.
Following the seizure, the drugs were turned over to the RCMP.
Khat, otherwise known as Catha Edulis, is a controlled substance in Canada. It is illegal to import or export it. The drug is chewed as a stimulant. It can make people more alert and bring about a feeling of euphoria. According to the Canadian Centre for Addictions, the plant is 'deeply embedded in social gatherings,' in parts of east Africa and the middle east. Consistent use of the drug can lead to addiction and cause anxiety and even psychosis, the Canadian Centre for Addictions warns.
It is not known whether any charges have been laid in connection with the seizure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
15 minutes ago
- National Post
Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic
Article content SAN ANTONIO — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced its patent related to a method to detect lung disease through flow cytometry analysis of sputum has been allowed by the Canadian Patent Office. This patent strengthens the international protection of the Company's diagnostic platform that powers its flagship test, CyPath® Lung. Article content 'As with the recent announcement of the award of our patent in China, this Canadian patent reflects our continued execution toward building long-term shareholder value through innovation, protection of our unique assets, and a clear focus on early cancer detection that can save lives,' said Maria Zannes, President and CEO of bioAffinity Technologies. Lung cancer is the leading cause of cancer death in Canada, according to the Canadian Cancer Society. In 2024, approximately 31,000 Canadians were diagnosed with lung cancer, and approximately 20,700 people died of the disease. More than 70% of the lung cancer deaths were linked to smoking. Article content 'We believe that the award of this patent by the Canadian Patent Office further validates the diagnostic platform behind CyPath® Lung, expands the global footprint of our intellectual property portfolio and highlights the strength of our science,' Ms. Zannes said. 'Recent case studies highlight CyPath Lung's ability to detect lung cancer at its earliest stages, making our test all the more valuable in Canada where 50% of all lung cancer cases are diagnosed late at Stage IV with the five-year survival rate overall of about 19% in Canada, according to government statistics.' Article content The Canadian patent (Patent No. 3,136,245) – titled 'System and Method for Determining Lung Health' – protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum and the use of flow cytometry to determine the presence of lung cancer cells in the sputum. Article content CyPath® Lung is the Company's first commercial product, with clinical study results demonstrating 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Article content About CyPath® Lung Article content CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit Article content About bioAffinity Technologies, Inc. Article content bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Article content Forward-Looking Statements Article content Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the benefits to be derived from the patent, the Company's ability to safeguard its intellectual property, and the ability to market CyPath ® Lung in Canada, and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws. Article content Article content Article content Article content Article content Contacts Article content bioAffinity Technologies Article content Article content Julie Anne Overton Article content Article content Director of Communications Article content Article content
CTV News
15 minutes ago
- CTV News
Man dead following morning shooting near Dundas and Dupont
Video A man is dead following an early morning shooting in the Junction area. CP24's Arda Zakarian reports.
CBC
15 minutes ago
- CBC
Don't swim alone, Lifesaving Society stresses in kickoff to drowning prevention week
Officials with the Lifesaving Society are highlighting the importance of swimming with others and wearing a life-jacket as they mark another National Drowning Prevention Week. It comes as more people hit the water for the summer amid a spate of recent drowning deaths in the London area, including the drowning of a 17-year-old in Chatham, an 18-year-old man in Ipperwash, and a 35-year-old man in Port Burwell. The week-long safety campaign began on Sunday, the same day Stratford police say a 13-year-old Hamilton girl drowned while swimming in the reservoir of Wildwood Conservation Area. This year, the national volunteer organization and registered charity is focusing on educating the public about the dangers of swimming alone. The organization says swimming alone was a factor in roughly 56 per cent of drowning deaths in Ontario last year involving adults aged 35 to 64, and 69 per cent of deaths involving adults 65 and older. In young children five and under, absent or distracted supervision was a factor in 97 per cent of drownings, officials say. "Drowning is fast, and it's often silent, so we're looking at ways that you can be safer together, whether that's with someone else, or a parent being within arm's reach, or whether it's with your life jacket," said Stephanie Bakalar, a spokesperson for the Lifesaving Society's Ontario branch. "We have seen quite a few drownings this year, on par with the last few years happening in July, and it is often related to not being able to swim. It's a huge risk factor," she said. Nearly half of all reported drownings in the province last year happened in a lake or pond. Nineteen per cent involved a river, 15 per cent a bathtub, and 11 per cent a pool. Just one per cent occurred in lifeguard-supervised settings. Officials urge caution during drowning prevention week 15 hours ago Another major risk factor includes not wearing a life-jacket, including while boating. In at least 86 per cent of boating-related drownings last year, the victim was not wearing a life-jacket, the society says. "I think there's a misconception with life jackets that they're bulky, cumbersome, difficult. 'I don't need a life jacket,' is the attitude of a lot of people. 'I can swim. I'm on the boat, I'll be fine,'" Bakalar said. "Once you've been in an accident on a boat or fallen overboard, you're not going to be able to get to your life-jacket to put it on. Same as you're not going to wait to put a seat belt on until after you've crashed your car." She says modern life jackets come in a variety of styles and models, including inflatable ones that stay flat until you need them. Bakalar recommends people always swim with someone who knows how to swim or has lifesaving training, or to swim where there are lifeguards supervising. Children should always be actively watched at all times, she said. Taking or brushing up on swimming lessons is also a great way to stay safe in the water, she said, and the knowledge gained through lifesaving training can be beneficial even if you don't plan to become a lifeguard.
